Executive Director, Lifecycle Leader

About   Iovance Biotherapeutics, Inc.   Iovance Biotherapeutics , Inc.  is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The  Iovance TIL platform  spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit  www.iovance.com . Amtagvi® and its accompanying design marks, Proleukin ® , Iovance ® , and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on  www.iovance.com . Overview The Lifecycle leader (LCL) is responsible for shaping the program vision, strategic context, and lifecycle plan (LCP) across indications globally. The LCL oversees the development and execution of the LCP in line with the company strategy. They are able to navigate complex program challenges, the commercial and development landscape and assess and prioritize development in future indications. Essential Functions and Responsibilities • The LCL is responsible for shaping the program's cross-functional vision, strategic context, and lifecycle plan (LCP) for both current and future business opportunities. • The LCL, in partnership with the Program Manager, will work with leadership & SMEs (subject matter experts) to build out appropriate internal ways of working to enable best practices around development of data driven recommendations, decision making and communication. • As the single point of accountability in a cross-functional team, the LCL ensures timely delivery and manages the associated execution plan and milestones, closely aligning them with the approved LCP. • The LCL oversees integration across Iovance involving multiple stakeholders to ensure optimal program execution in line with program strategy and LCP. • Collaborating with functional team leaders, the LCL fosters alignment across the different sub -teams to ensure execution will achieve team and corporate goals (Commercial Team, Development Team, Regulatory Team etc.) • Serving as a point of triage, the LCL facilitates clear decision-making by incorporating cross-functional input to address high-impact issues. This involves co-creating solutions to complex challenges in real time. • The LCL leads the team in framing program needs and develops a range of options and recommendations for presentation to the Executive Leadership Team (ELT). The LCL ensures transparent communication with senior leadership, highlighting relevant scenarios, assumptions, and risks to inform decision-making and trade-offs. The LCL also represents the enterprise mindset and ensures all relevant functional perspectives have been considered. • The LCL ensures the inclusion of subject matter experts (SMEs) and situational members in discussions, guided by a predefined agenda set with guidance from the Program Manager. • The LCL is accountable to the ELT for program recommendatio